Efficacy of canagliflozin versus liraglutide, alternative to bolus insulin in patients with basal-bolus regimen

INTERVENTION: The group which changes ultra‐rapid insulin to canagliflozin 100mg p.o. for 24 weeks. The group which changes ultra‐rapid insulin to liraglutide 0.9mg s.c. for 24 weeks. CONDITION: Type 2 diabetes mellitus PRIMARY OUTCOME: The reduction degree of the HbA1c in 12 and 24 weeks. INCLUSION CRITERIA: (1) We screened type 2 diabetic patients who regularly attended Toho University Oomori Hospital. (2) Disease duration 1 to 25 years. (3) Patient taking basal‐bolus insulin therapy, with insulin glargine or insulin degurudegu, and ultra‐rapid insulin more than 6 months. (4) Glycated hemoglobin (HbA1c) of less than 7.5%, and stable glycemic control with HbA1c variation less than 1.0% during the preceding 2 months. (5) Body mass index (BMI) is over 22. (6) Negative history of GLP‐1 agonist. (7) Patient taking equal or less than two kinds of oral anti‐diabetes drugs, except DPP‐4 inhibitor or SGLT2 inhibitor. (8) Adults who are 20 years or older. (9) Patients who can understand consent brief and other explanation documents having the ability of the agreement about participation in this examination.